ABSTRACT
Neurodevelopmental disorders have been linked to numerous genes, particularly pathogenic variants in genes encoding postsynaptic scaffolding proteins, like SHANK3. This study aims to provide insights into the cardiovascular profile of patients with pathogenic SHANK3 variants, expanding beyond the well-established associations with neurodevelopmental disorders and epilepsy. We conducted a prospective study involving patients affected by neurodevelopmental disorders with pathogenic SHANK3 variants. Comprehensive cardiovascular assessments were performed and molecular genetic testing included chromosomal microarray followed by clinical exome sequencing. We identified five patients with de novo SHANK3 variants, all of whom exhibited cardiac involvement, including myocardial dysfunction, congenital heart disease (patent ductus arteriosus), and a case of postictal atrial fibrillation. Our findings emphasize an elevated risk of cardiovascular abnormalities in patients with SHANK3 pathogenic variants compared to prior reports. Despite their young age, these patients displayed significant cardiac abnormalities. The study highlights the necessity of integrating cardiac evaluation and ongoing cardiovascular monitoring into multidisciplinary care, facilitating early detection of heart failure and assessment of the risk of sudden unexpected death in epilepsy (SUDEP). Further research is needed to elucidate the underlying mechanisms of cardiac manifestations in SHANK3 mutation carriers.
ABSTRACT
Dystrophinopathies, such as Duchenne and Becker muscular dystrophy, frequently lead to cardiomyopathy, being its primary cause of mortality. Detecting cardiac dysfunction early is crucial, but current imaging methods lack insight into microstructural remodeling. This study aims to assess the potential of cardiac magnetic resonance (CMR) parametric mappings for early detection of myocardial involvement in dystrophinopathies and explores whether distinct involvement patterns may indicate impending dysfunction. In this prospective study, 23 dystrophinopathy patients underwent CMR with tissue mappings. To establish a basis for comparison, a control group of 173 subjects was analyzed. CMR protocols included SSFP, T2-weighted and T1-weighted sequences pre and post gadolinium, and tissue mappings for native T1 (nT1), extracellular volume (ECV), and T2 relaxation times. The difference between the left ventricular posterior wall and the interventricular septum was calculated to reveal asymmetric myocardial involvement. Significant differences in LV ejection fraction (LVEF), myocardial mass, and late gadolinium enhancement confirmed abnormalities in patients. Tissue mappings: nT1 (p < 0.001) and ECV (p = 0.002), but not T2, displayed substantial variations, suggesting sensitivity to myocardial involvement. Asymmetric myocardial involvement in nT1 (p = 0.01) and ECV (p = 0.012) between septal and LV posterior wall regions was significant. While higher mapping values didn't correlate with dysfunction, asymmetric involvement in nT1 (ρ=-0.472, p = 0.023) and ECV (ρ=-0.460, p = 0.049) exhibited a significant negative correlation with LVEF. CMR mappings show promise in early myocardial damage detection in dystrophinopathies. Although mapping values may not directly correspond to dysfunction, the negative correlation between asymmetric involvement in nT1 and ECV with LVEF suggests their potential as early biomarkers. Larger, longitudinal studies are needed for a comprehensive understanding and improved risk stratification in dystrophinopathies.
Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Enterovirus , Myocarditis , Myocardium , Magnetic Resonance SpectroscopyABSTRACT
Introducción: Muchos antivirales, como la hidroxicloroquina, se han utilizado para el tratamiento de COVID-19. La prolongación del QTc es un efecto adverso preocupante, escasamente estudiado en pediatría. Pacientes y métodos: Los pacientes pediátricos con COVID-19 que recibieron tratamiento antiviral se emparejaron (1:2) con controles no infectados ni expuestos al tratamiento. Se analizaron prospectivamente los electrocardiogramas basales, en las primeras 72 horas de tratamiento y posterior a 72 horas. Resultados: Once (22,9%) de 48 pacientes pediátricos ingresados por COVID-19 (marzo a julio del 2020) recibieron terapia antiviral. Todos presentaban patologías de base; destacando cardiopatías (4/11; 36,4%) e inmunosupresión (3/11; 27,3%); 5/11 (45,5%) recibían tratamiento de base con potencial efecto sobre el QTc. No hubo diferencias en el QTc basal entre casos y controles: 414,8 ms (49,2) vs. 416,5 ms (29,4) (p = 0,716). Se observó QTc prolongado basal en 2/11 casos y 2/22 controles. De los casos, 10/11 (90,9%) recibieron hidroxicloroquina, principalmente asociada a azitromicina (8/11; 72,7%); tres recibieron lopinavir/ritonavir, uno remdesivir. La mediana de incremento del QTc tras 72 horas fue de 28,9 ms (IQR 48,7) (p = 0,062); 4/11 (36,4%) presentaron un QTc largo, de los cuales en tres ≥ 500 ms. En uno se paró el tratamiento (QTc 510 ms) pero no se documentaron arritmias ventriculares. Conclusiones: El uso de fármacos antivirales causó un incremento del QTc tras 72 horas de tratamiento, considerándose un QTc largo en el 36,4% de los pacientes, aunque no se objetivaron eventos arrítmicos. El uso de hidroxicloroquina y antivirales requiere monitorización activa del QTc y se recomienda suspender el tratamiento si el QTc > 500 ms. (AU)
Introduction: Many antiviral agents, such as hydroxychloroquine, have been used to treat COVID-19, without being broadly accepted. QTc prolongation is a worrisome adverse effect, scarcely studied in pediatrics. Patients and methods: Pediatric patients affected from COVID-19 who received antivirals were matched (1:2) with controls not infected nor exposed. Electrocardiograms were prospectively analyzed at baseline, during the first 72 h in treatment and after 72 h. Results: Eleven (22.9%) out of 48 patients admitted due to COVID-19 (MarchJuly 2020) received antiviral therapy. All had underlying diseases: congenital heart disease (4/11; 36.4%) and immunosuppression (3/11; 27.3%) stand out. 5/11 (45.5%) received treatment at baseline with a potential effect on QTc. There where no differences observed in the baseline QTc between cases and controls: 414.8 ms (49.2) vs. 416.5 ms (29.4) (p = 0.716). Baseline long QT was observed in 2/11 cases and 2/22. Among cases, 10/11 (90.9%) received hydroxychloroquine, mainly associated with azithromycin (8/11; 72.7%), 3 received lopinavir/ritonavir and one remdesivir. The median increase in QTc after 72 h under treatment was 28.9 ms (IQR 48.7) (p = 0.062). 4/11 (36.4%) patients had a long QTc at 72 h, resulting in 3 patients ≥500 ms; treatment was stopped in one (QTc 510 ms) but ventricular arrhythmias were not documented. Conclusions: The use of antivirals caused an increase on the QTc interval after 72 h of treatment, being the QTc long in 36.3% of the patients, although no arrhythmic events were observed. The use of hydroxychloroquine and antivirals requires active QTc monitoring and it is recommended to discontinue treatment if QTc >500 ms. (AU)
Subject(s)
Humans , Infant, Newborn , Child, Preschool , Child , Adolescent , Health Sciences , Coronavirus , Hydroxychloroquine , Electrocardiography , Antiviral Agents , PediatricsABSTRACT
Introducció. Lanèmia megaloblàstica és una causa poc freqüent de pancitopènia en lactants. La seva principal etiologia és el dèficit matern de vitamina B12 en recent nascuts alimentats exclusivament amb lactància materna, toti que en alguns casos aquest déficit pot ser secundari auna anèmia perniciosa materna.Cas clínic. Lactant de 3 mesos que va consultar a urgènciesper vòmits i estancament ponderal de 3 setmanesdevolució. En lanalítica sanguínia destacava anèmia (hemoglobina 6,5 g/dL), trombocitopènia (12 x10E9/L) i leucopènia (5,5 x10E9/L) amb neutropènia severa (0,11x10E9/L). Els nivells de vitamina B12 van resultar ser de60 pg/mL. Davant la confirmació danèmia megaloblàstica,es completà lestudi amb una analítica sanguínia i gastroscòpia materna que mostraren una anèmia perniciosa, prèviament desconeguda, causant del dèficit de cobalamina ala pacient. Es va iniciar suplementació amb vitamina B12endovenosa, comprovant-se bona resposta reticulocitària,augment de leucòcits i manteniment de xifra normal deplaquetes i hemoglobina.Comentaris. Les alteracions neurològiques secundàries aldéficit de vitamina B12 poden arribar a ser severes, i enalgunes ocasions fins i tot irreversibles. La importància delseu diagnòstic és la instauració de suplementació precoçper a corregir el dèficit i així millorar el pronòstic. (AU)
Introducción. La anemia megaloblástica es una causa poco frecuente de pancitopenia en lactantes. Su principal etiología es eldéficit materno de vitamina B12 en recién nacidos alimentadosexclusivamente con lactancia materna, aunque en algunos casospuede ser secundario a una anemia perniciosa materna.Caso clínico. Lactante de 3 meses que consultó a urgencias porvómitos y estancamiento ponderal de 3 semanas de evolución. Enla analítica sanguínea destacaba anemia (hemoglobina 6,5 g/dL), trombocitopenia (12 x10E9/L) y leucopenia (5,5 x10E9/L) con neutropenia severa (0,11 x10E9/L). Los niveles de vitamina B12 resultaron ser de 60 pg/mL. Ante la confirmación de anemia megaloblástica, se completó el estudio con una analítica sanguínea ygastroscopia materna que mostraron una anemia perniciosa, previamente desconocida, causante del déficit de cobalamina a la paciente. Se inició suplementación con vitamina B12 endovenosa,comprobándose buena respuesta reticulocitaria, aumento de leucocitos y mantenimiento de cifra normal de plaquetas y hemoglobina.Comentarios. Las alteraciones neurológicas secundarias al déficitpueden llegar a ser severas, y en algunas ocasiones incluso irreversibles. La importancia de su diagnóstico es la instauración de suplementación precoz para corregir el déficit y así mejorar el pronóstico. (AU)
Introduction. Megaloblastic anemia is a rare cause of pancytopeniain infants. Its main etiology is maternal vitamin B12 deficiency inexclusively breastfed newborns, although in some cases it may besecondary to maternal pernicious anemia.Case report. Three-month-old infant who consulted the emergencydepartment for vomiting and a three-week failure to thrive. Laboratory evaluation was significant for anemia (hemoglobin 6,5 g/dL),thrombocytopenia (12 x109/L) and leukopenia (5,5 x109/L) withsevere neutropenia (0,11 x109/L). Vitamin B12 levels were foundto be 60 pg/mL. Upon confirmation of megaloblastic anemia, thestudy was completed with a blood test and maternal gastroscopythat showed a previously unknown pernicious anemia causingthe patient's cobalamin deficit. Vitamin B12 supplementationwas started intravenously, proving good reticulocyte response,increase of leukocytes and normalization of platelet and hemoglobin values.Comments. Neurological alterations secondary to vitamin B12 deficit can be severe, and sometimes even irreversible. The importance of its diagnosis is the establishment of early supplementation to correct the deficit and thus improve the prognosis. (AU)